Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Iowa Livmarli Coverage | Op…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.04.48

    Livmarli (maralixibat) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.48 alerts

    Get alerted when Policy 05.04.48 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Livmarli (maralixibat) for cholestatic pruritus associated with Alagille syndrome or progressive familial intrahepatic cholestasis, subject to clinical, age, prescriber, exclusion, continuation, and dosing requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyLivmarli (maralixibat) Coverage Criteria
    Policy CodePolicy 05.04.48
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the applicable criteria and ensure the medication is prescribed by or in consultation with a hepatologist or gastroenterologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved disease indications
    6 monthsInitial authorization period
    12 monthsContinuation authorization period
    3 monthsMinimum age for Alagille syndrome treatment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Minimum age for PFIC treatment
    120 mL or 60 tabletsMaximum standard 30-day quantity

    Coverage Criteria

    Initial therapy: cholestatic pruritus in Alagille syndrome

    Authorization of 6 months may be granted when all of the following criteria are met.

    ALGS initial therapy requirements

    • One of four accepted ALGS diagnostic pathways

      • Diagnosis established by genetic testing, such as JAG1 or NOTCH2 gene variants.
      • Family history of ALGS and one or more major clinical features of ALGS.
      • Bile duct paucity and three or more major clinical features of ALGS.
      • Four or more major clinical features of ALGS.
    • Additional clinical requirements

      • Evidence of cholestasis, such as an elevated serum bile acid level.
      • No history or presence of another concomitant liver disease, such as biliary atresia, PFIC, or liver cancer.
      • Has not received a liver transplant.
      • Member is 3 months of age or older.Age >= 3 months

    Initial therapy: pruritus in progressive familial intrahepatic cholestasis

    Authorization of 6 months may be granted when all of the following criteria are met.

    PFIC initial therapy requirements

    • Confirmed molecular diagnosis

      • Confirmed molecular diagnosis of PFIC, such as ATP8B1, ABCB11, ABCB4, TJP2, or MYO5B gene variants.
    • Additional clinical requirements

      • Evidence of cholestasis, such as an elevated serum bile acid level.
      • No other concomitant liver disease, such as biliary atresia, liver cancer, or an alternate non-PFIC-related etiology of cholestasis.
      • Has not received a liver transplant.

    Continuation therapy

    Authorization of 12 months may be granted for all members, including new members, when the member is experiencing benefit from therapy.

    • Member is experiencing benefit from Livmarli therapy, such as improvement in pruritus.Documented clinical benefit

      Applies to all members, including new members, requesting continuation of therapy.

    Coverage will not be provided for members with PFIC type 2 caused by ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) protein.

    Coverage will not be provided for members with prior or active hepatic decompensation, including events such as variceal hemorrhage, ascites, or hepatic encephalopathy.

    Livmarli must not be used concomitantly with another ileal bile acid transporter (IBAT) inhibitor, such as Bylvay.

    Livmarli is considered not medically necessary when the member does not meet the policy's stated coverage criteria.

    Initial Therapy Criteria

    Initial ALGS authorization

    Authorization of 6 months may be granted when all criteria for Alagille syndrome treatment are met.

    ALGS initial authorization

    • One of four accepted ALGS diagnostic pathways

      • Diagnosis established by genetic testing, such as JAG1 or NOTCH2 gene variants.
      • Family history of ALGS and one or more major clinical features of ALGS.
      • Bile duct paucity and three or more major clinical features of ALGS.
      • Four or more major clinical features of ALGS.
    • Required clinical criteria

    Continuation of Therapy

    Continuation of therapy

    Authorization of 12 months may be granted for all members, including new members, requesting continuation of therapy.

    • Member is experiencing benefit from therapy, such as improvement in pruritus.Documented clinical benefit

      Applies to all members, including new members, requesting continuation of therapy.

    Procedures and Billing Codes

    Procedures and Billing Codesmixed
    N/ANot applicable (N/A)

    Prior Authorization and Documentation

    Prior Authorization

    Specialist Prescriber or Consultation Required

    Prior authorization is required, and Livmarli must be prescribed by or in consultation with a hepatologist or gastroenterologist.

    • Specialist requirement: Hepatologist or gastroenterologist prescribing or consultation.
    Documentation Required

    Initial Diagnostic Documentation

    For initial requests, submit genetic testing results confirming a diagnosis of Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC), if applicable.

    • Initial requests: Genetic testing documentation confirming ALGS or PFIC.
    Documentation Required

    Clinical Background

    Livmarli (maralixibat) is an ileal bile acid transporter inhibitor used to treat cholestatic pruritus associated with Alagille syndrome or progressive familial intrahepatic cholestasis. Coverage depends on documented diagnosis and the applicable clinical requirements, including age, cholestasis, absence of specified exclusions, and response to therapy when continuation is requested.

    Disease Features

    Major clinical features of Alagille syndrome
    Hepatic abnormalitye.g., cholestasis
    Cardiac abnormalitye.g., stenosis of the peripheral pulmonary artery and its branches
    Skeletal abnormalitye.g., butterfly vertebrae
    Ophthalmologic abnormalitye.g., posterior embryotoxon
    Characteristic facial featurese.g., triangular-shaped face with a broad forehead and a pointed chin, bulbous tip of the nose, deeply set eyes, and hypertelorism
    Vascular abnormalitiese.g., intracranial bleeds and systemic vascular anomalies
    Renal structural or functional abnormality

    30-Day Quantity Limits

    Quantity limit
    FormulationLivmarli 9.5 mg/mL oral solution
    Standard limit120 mL (4 bottles)
    Limit periodPer 30 days
    Quantity limit
    FormulationLivmarli 19 mg/mL oral solution
    Standard limit60 mL (2 bottles)
    Limit periodPer 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyLivmarli (maralixibat) Coverage Criteria
    Policy CodePolicy 05.04.48
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the applicable criteria and ensure the medication is prescribed by or in consultation with a hepatologist or gastroenterologist.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation of TherapyProcedures and Billing CodesPrior Authorization and DocumentationClinical BackgroundDisease Features30-Day Quantity Limits
  1. Member is 12 months of age or older.Age >= 12 months
    • Evidence of cholestasis, such as an elevated serum bile acid level.
    • No history or presence of another concomitant liver disease, such as biliary atresia, PFIC, or liver cancer.
    • Has not received a liver transplant.
    • Member is 3 months of age or older.Age >= 3 months

    Initial PFIC authorization

    Authorization of 6 months may be granted when all criteria for progressive familial intrahepatic cholestasis treatment are met.

    PFIC initial authorization

    • Confirmed molecular diagnosis of PFIC, such as ATP8B1, ABCB11, ABCB4, TJP2, or MYO5B gene variants.
    • Evidence of cholestasis, such as an elevated serum bile acid level.
    • No other concomitant liver disease, such as biliary atresia, liver cancer, or an alternate non-PFIC-related etiology of cholestasis.
    • Has not received a liver transplant.
    • Member is 12 months of age or older.Age >= 12 months

    Continuation Response Documentation

    For continuation requests, submit chart notes or medical records documenting benefit from therapy, such as improvement in pruritus.

    • Continuation requests: Documentation of clinical benefit from Livmarli.
    Denial Risk

    PFIC Type 2 With Nonfunctional BSEP

    Coverage will not be provided for members with PFIC type 2 and variants in the ABCB11 gene resulting in a non-functional or complete absence of the bile salt export pump (BSEP) protein.

    • Exclusion: PFIC type 2 with non-functional or absent BSEP protein due to ABCB11 variants.
    Denial Risk

    Hepatic Decompensation Exclusion

    Coverage will not be provided for members with prior or active hepatic decompensation events.

    • Examples include variceal hemorrhage, ascites, or hepatic encephalopathy.
    • Applies to both prior and active hepatic decompensation events.
    Denial Risk

    Failure to Meet Criteria

    Livmarli is considered not medically necessary when the member does not meet the applicable policy criteria.

    • Confirm that all required coverage criteria are satisfied before submitting the request.
    Denial Risk

    No Concomitant IBAT Inhibitor Use

    The requested medication must not be used concomitantly with another ileal bile acid transporter (IBAT) inhibitor.

    • Concomitant use prohibited: Other IBAT inhibitors, such as Bylvay.
    e.g., abnormally small size and cysts
    Quantity limit
    FormulationLivmarli 10 mg tablets
    Standard limit60 tablets
    Limit periodPer 30 days
    Quantity limit
    FormulationLivmarli 15 mg tablets
    Standard limit60 tablets
    Limit periodPer 30 days
    Quantity limit
    FormulationLivmarli 20 mg tablets
    Standard limit60 tablets
    Limit periodPer 30 days
    Quantity limit
    FormulationLivmarli 30 mg tablets
    Standard limit30 tablets
    Limit periodPer 30 days
    Quantity limit
    FormulationLivmarli 9.5 mg/mL oral solution
    Quantity limit120 mL (4 bottles) per 30 days
    Treatment indication listedTreatment of ALGS
    Quantity limit
    FormulationLivmarli 19 mg/mL oral solution
    Quantity limit60 mL (2 bottles) per 30 days
    Treatment indication listedTreatment of ALGS
    Quantity limit
    FormulationLivmarli 10 mg tablets
    Quantity limit60 tablets per 30 days
    Treatment indication listedTreatment of PFIC
    Quantity limit
    FormulationLivmarli 15 mg tablets
    Quantity limit60 tablets per 30 days
    Treatment indication listedTreatment of PFIC
    Quantity limit
    FormulationLivmarli 20 mg tablets
    Quantity limit60 tablets per 30 days
    Treatment indication listedTreatment of PFIC
    Quantity limit
    FormulationLivmarli 30 mg tablets
    Quantity limit30 tablets per 30 days
    Treatment indication listedTreatment of PFIC